IGC Pharma, Inc.
Symbol: IGC (NYSE)
0.37
▼ (-0.98%) -0.004
Company Description:
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
Key Stats
- Today's Open: $0.373
- Today's High: $0.395
- Today's Low: $0.352
- Today's Volume: 1.17M
- Yesterday Close: $0.3686
- Yesterday High: $0.4047
- Yesterday Low: $0.3643
- Yesterday Volume: 1.69M
- Last Min Volume: 2
- Last Min High: $0.365
- Last Min Low: $0.362
- Last Min VWAP: $0.362
Company Profile
- Name: IGC Pharma, Inc.
- Website: https://www.igcinc.us
- Listed Date: 2006-04-13
- Location: POTOMAC, MD
- Market Status: Active
- CIK Number: 0001326205
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $30.92M
- Round Lot: 100
- Outstanding Shares: 83.89M
- Asset Type: CS
RECENT FILINGS FOR IGC
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-07-18 | S-3 | View |
| 2025-06-27 | 10-K | View |
| 2025-06-17 | 8-K | View |
| 2025-05-15 | 5 | View |
| 2025-05-15 | 5 | View |
| 2025-05-15 | 5 | View |
| 2025-05-15 | 5 | View |
| 2025-02-14 | 10-Q | View |
| 2024-11-12 | 10-Q | View |
| 2024-09-27 | 4 | View |
| 2024-09-27 | 8-K | View |
| 2024-08-27 | 8-K | View |
| 2024-08-14 | SC 13D/A | View |
| 2024-08-12 | 4 | View |
| 2024-08-09 | 144 | View |
| 2024-08-07 | 10-Q | View |
| 2024-08-07 | UPLOAD | View |
| 2024-08-02 | 8-K | View |
| 2024-07-09 | DEFA14A | View |
| 2024-07-08 | DEF 14A | View |
Latest News on IGC